Beyond cell-cell contact: therapeutic potential of Eph signaling in central nervous system tumors

TL;DR

This paper explores how Eph signaling, a system involved in cell communication, can be targeted to treat central nervous system tumors like glioblastoma and medulloblastoma.

Contribution

The paper identifies Eph/ephrin signaling as a dualistic biomarker and therapeutic target in CNS tumors, proposing combinatorial strategies for treatment.

Findings

EphA2 and EphA3 overexpression correlates with higher glioma grade and invasiveness.

Ephrin-A1 and ephrin-A5 suppress tumor growth by inhibiting proliferation and migration.

Targeting Eph/ephrin with cytotoxins, inhibitors, and immunomodulators shows anti-tumor efficacy in preclinical models.

Abstract

Eph receptor tyrosine kinases and their membrane-bound ephrin ligands constitute a unique bidirectional signaling system that orchestrates cell adhesion, migration, proliferation, and vascular patterning, processes frequently co-opted in malignancy. We conducted an integrative review of preclinical models and clinical cohorts to delineate Eph/ephrin expression landscapes and evaluate functional outcomes in central nervous system neoplasms. In gliomas, particularly glioblastoma multiforme, overexpression of EphA2 and EphA3 correlates with higher tumor grade and increased invasiveness. Conversely, ephrin-A1 and ephrin-A5 exhibit tumor-suppressive properties by promoting receptor internalization and degradation, thereby inhibiting glioma cell proliferation and migration. In medulloblastoma, elevated expression of EphB1 and EphA4 is associated with enhanced angiogenesis and migratory capacity, contributing to tumor progression. In meningiomas, aberrant activation of EphA2 and EphB1 promotes proliferation through engagement with mTOR and ERBB3 signaling pathways. Emerging therapeutic strategies, including ligand-targeted cytotoxins, selective kinase inhibitors, chimeric antigen receptor T cells, and ephrin-based immunomodulators, demonstrate potent anti-tumor efficacy in preclinical settings, highlighting the translational potential of targeting the Eph/ephrin axis. The dualistic nature of Eph/ephrin signaling underscores its translational promise as both a biomarker framework and a precision-guided therapeutic target. Combinatorial receptor-ligand modulation strategies may advance the treatment of central nervous system malignancies by exploiting the context-dependent roles of Eph/ephrin interactions.

Figures